A less-frequent dosing schedule of a bone-modifying agent (BMA) for treatment of skeletal-related events related to metastatic breast cancer is noninferior to standard dosing, according to research published in JAMA...
A less-frequent dosing schedule of a bone-modifying agent (BMA) for treatment of skeletal-related events related to metastatic breast cancer is noninferior to standard dosing, according to research published in JAMA...
A...